Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems

US6180656A · kind A · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Chantal Fürstner · Neheim, DE
• Alexander Straub · Wuppertal, DE
• Ulrich Niewohner · Wermelskirchen, DE
• Thomas Jaetsch · Cologne, DE
• Achim Feurer · Wilhelmsfeld, DE
• Raimund Kast · Wuppertal, DE
• Johannes-Peter Stasch · Wuppertal, DE
• Elisabeth Perzborn · Wuppertal, DE
• Joachim Hutter · Leverkusen, DE
• Klaus Dembowsky · Boston, US

Key dates

• Filing date: Apr 6, 1999
• Grant date: Jan 30, 2001
• Expiry date: Apr 6, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the new use of 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives, some of which are known, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 have the meaning indicated in the description, as medicaments, and to new active compounds, in particular to their use as vasodilators, if appropriate in combination with organic nitrates and NO donors and if appropriate in combination with compounds which inhibit the degradation of cGMP.